Welcome to our dedicated page for COGNEX SEC filings (Ticker: CGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cognex Corporation filings document regulatory disclosures for an operating company focused on industrial machine vision products and automation technology. Its Form 8-K reports cover furnished operating results, quarterly cash dividends, share repurchase authorization, board and officer matters, annual meeting voting results, and changes in the company’s independent registered public accounting firm.
Proxy materials describe director elections, governance matters, executive compensation, shareholder voting procedures, and board committee oversight. The filing record also includes exhibit-based disclosures tied to financial-results releases and capital-return actions involving Cognex common stock.
Cognex Corporation executive Sheila Marie DiPalma, EVP of Employee Services, reported several equity compensation transactions. On February 17, 2026, she received a grant of 13,557 non-qualified stock options and 13,138 restricted stock units (RSUs), both at a price of $0.00. The options vest in five approximately equal annual installments starting one year after the grant date, while the RSUs vest 20%, 30%, and 50% on the first, second, and third anniversaries.
On February 18, 2026, 3,027 RSUs were exercised and converted into common stock at $0.00, increasing her directly held common shares, and 1,022 common shares at $56.72 were withheld to satisfy tax obligations related to the vesting. After these transactions, she held 8,587 shares of common stock directly and maintained derivative holdings including RSUs and stock options as reported.
COGNEX CORP director Robert Willett reported equity award activity tied to restricted stock units that vested on February 18, 2026. A total of 14,165 restricted stock units were converted into common shares at no cost and are held indirectly by the Willett Parkhill Investment Trust, where he is trustee and beneficiary and disclaims beneficial ownership beyond his economic interest.
To cover tax obligations on this vesting, the trust disposed of 6,849 common shares at $56.72 per share through share withholding rather than an open-market sale. The underlying RSU grant vests in tranches of approximately 20%, 30%, and 50% on the first, second, and third anniversaries of the February 18, 2025 grant date.
Cognex director Anthony Sun reported equity award activity and updated holdings. On February 18, 2026, 8,324 restricted stock units were exercised or converted at an exercise price of $0.00 per unit, resulting in 8,324 shares of common stock and bringing his directly held common stock to 332,172 shares.
On February 17, 2026, Sun received a grant of 4,817 restricted stock units, which each represent a right to one share of Cognex common stock and vest 100% on the first anniversary of the grant date. The filing also lists stock options and common shares held indirectly through Sun Management Associates, LLC, where he disclaims beneficial ownership beyond his pecuniary interest.
Cognex Corporation filed an amended report to update details on its change of independent auditor. The Audit Committee selected KPMG LLP as auditor for the fiscal year ending December 31, 2026, replacing Grant Thornton LLP after Grant Thornton completed its audit of the 2025 financial statements on February 13, 2026.
Grant Thornton’s reports on Cognex’s consolidated financial statements for the years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications. The company reports no disagreements or reportable events with Grant Thornton and states it did not consult KPMG on specific accounting issues or audit opinions during 2024, 2025, or through February 13, 2026.
Cognex Corp director Robert Willett exercised stock options and sold the resulting shares in a same-day transaction. On 02/13/2026 he exercised 2,148 non-qualified stock options at $39.44 per share, receiving 2,148 shares of common stock, then sold those 2,148 shares at an average price of $59.5011 per share under a Rule 10b5-1 trading plan. Following these transactions he reported no directly held common shares, while continuing to hold multiple option grants and restricted stock units, plus 15,804 common shares held indirectly through the Willett Parkhill Investment Trust, where he is trustee and beneficiary and disclaims beneficial ownership beyond his pecuniary interest.
Cognex Corporation announced that its Board of Directors has appointed Dr. Sami Atiya and Mr. Chris Donato as directors, effective March 2, 2026. Dr. Atiya’s term will run to the 2028 annual meeting, while Mr. Donato’s term will run to the 2026 annual meeting.
Dr. Atiya is expected to join the Nominating, Governance and Sustainability Committee, and Mr. Donato is expected to join the Compensation Committee. Each will receive a $50,000 annual cash retainer, plus $5,000 for Dr. Atiya’s committee role and $8,000 for Mr. Donato’s committee role, along with initial RSU grants valued at about $275,000 that vest after one year.
In connection with these appointments, former CEO Robert Willett and Dr. Dianne Parrotte will retire from the Board on March 2, 2026, continuing an ongoing refresh of Cognex’s board with independent directors who bring automation, AI, and enterprise sales expertise.
Cognex director Robert Willett reported exercising stock options and selling the resulting shares on 02/12/2026. He exercised options for 173,296 shares at $38.39 and 3,756 shares at $39.44, then sold all 177,052 shares of common stock at an average price of $58.3851 per share in open-market transactions.
The filing shows remaining direct holdings of multiple non-qualified stock options covering hundreds of thousands of shares with exercise prices from $33.04 to $90.5, plus 70,824 restricted stock units and 15,804 shares held indirectly by a trust where Willett is trustee and beneficiary. The stock option exercises were carried out under a pre-established Rule 10b5-1 trading plan.
Cognex Corp VP and PAO Laura A. MacDonald reported option exercises and share sales on 02/12/2026. She exercised 12,500 non-qualified stock options at $38.39 per share, receiving an equal number of common shares.
MacDonald then made open-market sales totaling 14,881 common shares: 2,381 shares at $56.56 and 12,500 shares at $57.2707, pursuant to Rule 10b5-1 trading plans. After these transactions, she directly owned 2,212 common shares, plus various option and restricted stock unit awards, and 20 shares were held indirectly by her child with beneficial ownership disclaimed except for any pecuniary interest.
Cognex Corporation insider plans a new stock sale. A person for whose account the securities are to be sold filed to sell 2,148 shares of Cognex common stock on NASDAQ through Fidelity Brokerage Services, with an aggregate market value of $127,808.48.
The shares were acquired on 02/13/2026 via an option granted on 02/20/2024, paid in cash. Over the prior three months, Robert J. Willett sold 177,052 Cognex common shares for gross proceeds of $10,300,974.15, indicating substantial recent selling activity.
An affiliate of Cognex (CGNX) filed a notice of proposed resale of Cognex common stock under Rule 144. The notice covers planned sales of 2,381 shares and 12,500 shares through Robert W. Baird & Co., with aggregate market values of $134,670.00 and $715,884.00 on the NASDAQ. Cognex had 165,707,920 shares outstanding at the time referenced. The securities to be sold were acquired primarily through RSU releases in 2024 and 2025 and the cash exercise of a stock option originally granted in 2017.